Фармакоэкономические исследования лекарственного обеспечения хронической обструктивной болезни легких в Узбекистане

Summary. Leading specialists (n = 91) of tertiary medical facilities were questioned on drug formulations and dosing of 102 commercially available medications routinely used in COPD. The aim of the surveillance was to determine critically important (essential) and additional (non-essential) medications using VEN-analysis (V – vital; E – essential; N -non-essential). Data of the surveillance were proceeded using an intellectual method. Distribution of drugs through VEN groups resulted in selection of medications effective in COPD. Critically important medication groups for inpatient and outpatient treatment of COPD were also determined.Резюме. На фармацевтическом рынке Узбекистана проводился опрос среди 91 ведущего врача специализированных учреждений с указанием формы и дозы лекарственных препаратов 102 торговых наименований, широко используемых при хронической обструктивной болезни легких (ХОБЛ). Цель опроса – проведение VEN-анализа, определение жизненно необходимых (Vital – V), необходимых (Essential – E) и второстепенных препаратов (Non5essential – N). После распределение лекарственных средств по VEN-группам были определены препараты, эффективность которых дает основания более широко применять их в лечении ХОБЛ. Определены группы лекарственных препаратов, которые необходимы для терапии ХОБЛ в стационарных и амбулаторных условиях

Pharmacoeconomic analysis of drugs used in traumatology

Drugs used in traumatology are analyzed in scientific studies. The process of treating patients was in-vestigated, types of diseases and associated conditions were analyzed. The nomenclature of drugs used in traumatology was studied, and groups of relatively effective and affordable drugs were identified. The re-sult of pharmacoeconomic analysis of drugs used in traumatology, the cost of treatment with a tablet num-ber 4 Alovell 70 mg compared with a tablet number 4 Ostalon 70 mg, defined savings in the amount of 44,930 for one patient and scientifically based rational use of funds